STOK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STOK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Stoke Therapeutics's Enterprise Value is $447.45 Mil. Stoke Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-114.77 Mil. Therefore, Stoke Therapeutics's EV-to-EBIT ratio for today is -3.90.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Stoke Therapeutics's Enterprise Value is $447.45 Mil. Stoke Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-112.30 Mil. Therefore, Stoke Therapeutics's EV-to-EBITDA ratio for today is -3.98.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Stoke Therapeutics's Enterprise Value is $447.45 Mil. Stoke Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $8.78 Mil. Therefore, Stoke Therapeutics's EV-to-Revenue ratio for today is 50.96.
The historical data trend for Stoke Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Enterprise Value | Get a 7-Day Free Trial | 708.18 | 1,978.98 | 666.99 | 136.79 | 42.20 |
Stoke Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | 136.79 | 116.71 | 240.88 | -37.71 | 42.20 |
For the Biotechnology subindustry, Stoke Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Stoke Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 241.529732 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.062 | + | 0 | - | 201.394 |
= | 42.20 |
Stoke Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 241.529732 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 2.062 | + | 0 | - | 201.394 |
= | 42.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (NAS:STOK) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Stoke Therapeutics's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 447.446 | / | -114.772 | |
= | -3.90 |
Stoke Therapeutics's current Enterprise Value is $447.45 Mil.
Stoke Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-114.77 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Stoke Therapeutics's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 447.446 | / | -112.303 | |
= | -3.98 |
Stoke Therapeutics's current Enterprise Value is $447.45 Mil.
Stoke Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.30 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Stoke Therapeutics's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 447.446 | / | 8.781 | |
= | 50.96 |
Stoke Therapeutics's current Enterprise Value is $447.45 Mil.
Stoke Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Stoke Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Barry Ticho | officer: Chief Medical Officer | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Ian F Smith | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Jonathan Allan | officer: General Counsel & Corp Sec | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
Huw M. Nash | officer: COO & CBO | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Atp Life Science Ventures, L.p. | 10 percent owner | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Atp Iii Gp, Ltd. | 10 percent owner | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Skorpios Trust | 10 percent owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Montrago Trustees Ltd | 10 percent owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Blue Horizon Enterprise Ltd | 10 percent owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Ezbon International Ltd | 10 percent owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Gene Liau | officer: EVP Research & Preclinical Dev | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Arthur A Levin | director | 1896 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Stephen J Tulipano | officer: CFO | C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Arthur Tzianabos | director | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Kaye Edward M. Md | director, officer: CEO | 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011 |
From GuruFocus
By Business Wire • 09-21-2023
By Business Wire • 11-21-2023
By Business Wire • 01-17-2024
By Business Wire • 09-20-2023
By GuruFocus Research • 11-09-2023
By Business Wire Business Wire • 05-03-2023
By Business Wire Business Wire • 05-02-2022
By Business Wire Business Wire • 11-29-2022
By PRNewswire PRNewswire • 10-18-2022
By Business Wire Business Wire • 01-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.